Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQ3AM0
|
|||
| Drug Name |
PTG-300
|
|||
| Synonyms |
Rusfertide; Rusfertide [USAN]; UNII-XM71MYX0IQ; XM71MYX0IQ; PTG-300FB; WHO 11456; 1628323-80-7; Isovaleryl-Asp-Thr-His-Phe-Pro-cyclo(Cys-Ile-Lys(palm-gamma-Glu)- Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys)-Lys-NH2
Click to Show/Hide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Hemochromatosis [ICD-11: 5C64.1Y] | Phase 2 | [1] | |
| Polycythemia vera [ICD-11: 2A20.4; ICD-10: D45] | Phase 2 | [2] | ||
| Company |
Protagonist Therapeutics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C114H181N27O28S2
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC1C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)N1)C(C)CC)NC(=O)C3CCCN3C(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CNC=N5)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)CC(C)C)C(=O)NC(CCCCN)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCC(=O)O)CC6=CC=CC=C6)C(=O)O
|
|||
| InChI |
1S/C114H181N27O28S2/c1-7-9-10-11-12-13-14-15-16-17-18-19-26-46-90(145)125-79(113(168)169)47-49-89(144)121-53-32-29-42-76-99(154)133-80(58-71-36-22-20-23-37-71)101(156)132-78(48-50-93(148)149)111(166)140-55-34-44-87(140)107(162)130-77(43-33-54-122-114(118)119)100(155)136-84(64-142)104(159)129-75(41-28-31-52-116)98(153)123-63-92(147)127-85(105(160)128-74(97(117)152)40-27-30-51-115)65-170-171-66-86(106(161)138-95(69(5)8-2)109(164)131-76)137-108(163)88-45-35-56-141(88)112(167)83(59-72-38-24-21-25-39-72)135-102(157)81(60-73-62-120-67-124-73)134-110(165)96(70(6)143)139-103(158)82(61-94(150)151)126-91(146)57-68(3)4/h20-25,36-39,62,67-70,74-88,95-96,142-143H,7-19,26-35,40-61,63-66,115-116H2,1-6H3,(H2,117,152)(H,120,124)(H,121,144)(H,123,153)(H,125,145)(H,126,146)(H,127,147)(H,128,160)(H,129,159)(H,130,162)(H,131,164)(H,132,156)(H,133,154)(H,134,165)(H,135,157)(H,136,155)(H,137,163)(H,138,161)(H,139,158)(H,148,149)(H,150,151)(H,168,169)(H4,118,119,122)/t69-,70+,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,95-,96-/m0/s1
|
|||
| InChIKey |
JRVOBXXOZFTSRF-GVIPULMVSA-N
|
|||
| CAS Number |
CAS 1628323-80-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepcidin (HAMP) | Target Info | Replacement | [3] |
| WikiPathways | Iron metabolism in placenta | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04202965) PTG-300 in Subjects With Hereditary Hemochromatosis. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04767802) PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Protagonist Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.